Payment overview · 2025
General Payments
$45.55
3 reported records · 3 companies
Healthcare provider profile · identity verified
Kenneth David Kiser, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAURENS, SC · NPI 1336191246
Verified facts
What the public records show
CMS Open Payments records show Kenneth David Kiser, MD received $45.55 in general payments during 2025 across 3 reported records.
SHIELD THERAPEUTICS INC accounted for 36.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.71 | 36.7% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $14.96 | 32.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.88 | 30.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $45.55 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 454 | 91 |
| Potassium Chloride | Potassium Chloride | 452 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 398 | 88 |
| Eliquis | Apixaban | 367 | 30 |
| Lisinopril | Lisinopril | 316 | 69 |
| Gabapentin | Gabapentin | 296 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 238 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 51 |
| Famotidine | Famotidine | 207 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 187 | 63 |
| Losartan Potassium | Losartan Potassium | 185 | 47 |
| Sertraline Hcl | Sertraline Hcl | 182 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 30 |
| Furosemide | Furosemide | 159 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 22 |
| Omeprazole | Omeprazole | 153 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 39 |
| Allopurinol | Allopurinol | 112 | 30 |
| Metformin Hcl Er | Metformin Hcl | 110 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 19 |
| Montelukast Sodium | Montelukast Sodium | 108 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 19 |
| Carvedilol | Carvedilol | 105 | 20 |
| Jardiance | Empagliflozin | 105 | 20 |
| Donepezil Hcl | Donepezil Hcl | 104 | 11 |
| Memantine Hcl | Memantine Hcl | 102 | 12 |
| Spironolactone | Spironolactone | 90 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 15 |
| Alprazolam | Alprazolam | 86 | 11 |
| Trazodone Hcl | Trazodone Hcl | 82 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 16 |
| Januvia | Sitagliptin Phosphate | 79 | 11 |
| Ozempic | Semaglutide | 78 | 14 |
| Metformin Hcl | Metformin Hcl | 75 | 14 |
| Mirtazapine | Mirtazapine | 74 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | suppressed |
| Torsemide | Torsemide | 68 | 14 |
| Sucralfate | Sucralfate | 67 | suppressed |
| Niacin Er | Niacin | 59 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 58 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 14 |
| Finasteride | Finasteride | 55 | 12 |
| Valsartan | Valsartan | 55 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 12 |
| Mupirocin | Mupirocin | 46 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 13 |
| Brilinta | Ticagrelor | 36 | suppressed |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 30 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Simvastatin | Simvastatin | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Prednisone | Prednisone | 21 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $45.55 · 3 records | SHIELD THERAPEUTICS INC | ACCRUFER, AIRSUPRA, CT THROMBECTOMY SYSTEM KIT, FLOWTRIEVER CATHETER, S | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error